The American pharmaceutical company, Gilad Sciences, has formally applied for a "conditional marketing license" for "Remdisfer" as a new anti-coronavirus (Covid-19) in the European market, according to the European Medicines Agency (Emma) the day before yesterday, in Amsterdam.
"The benefits and risks of (RMD) are evaluated within a reduced timetable, and an opinion can be issued within weeks, depending on the strength of the data provided, and whether more information is needed to support the evaluation," the agency said in a statement. Once approved, this would be the first approval of a drug to treat Covid-19 in Europe.
This comes, at a time when a study published in the journal "Nature", yesterday, showed that the drug "Remdisfer" prevented the development of the disease in the lung in monkeys infected with the emerging corona virus.
Relevant authorities have authorized the use of "remdisfer" on an exceptional basis in critical patients in the United States, India and South Korea. It is also used by some European countries within the programs of humanitarian cases.
Human trials are still ongoing, and preliminary data have shown that the drug helped patients recover from disease faster than others.
The researchers said in the study, that the macaques that received the drug did not show any signs of a respiratory disease, and less damage was done to the lungs.